Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference ...

Shares of Summit Therapeutics (NASDAQ: SMMT) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning. Summit has been a tremendous winner over the past ...

Summit Therapeutics released more data from another HARMONi phase 3 trial. Results were "mixed," which perhaps led to some disappointment in this stock, which had rocketed higher over the past year.

Ivonescimab plus chemo cut disease progression risk by 48% vs. chemo alone (HR=0.52). Fatal TEAEs were lower with ivonescimab (1.8%) vs. chemo alone (2.8%) in Phase 3 trial. Get the Strategy to ...

Beam Therapeutics said the Food and Drug Administration has granted an orphan drug designation to its treatment for a genetic disorder that affects the lungs and or liver. The Cambridge ...

Edgewise Therapeutics' valuation is heavily reliant on DMD/BMD programs, with upcoming phase-2 readouts likely to disappoint and trigger a sharp stock decline. We believe that sevasemten's ...

CHICAGO--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with traditional biology research to accelerate ...

Fate Therapeutics, Inc. (NASDAQ:FATE) announced today that it will present groundbreaking clinical data from its Phase 1 trial of FT819, an off-the-shelf, iPSC-derived CAR T-cell therapy ...

One of the books reviewed in this issue is Shannon T.L. Kearns’ “No One Taught Me How to Be a Man,” centering on his journey transitioning to his proper self. I mentioned the title to a friend who ...